NCT04930120

Brief Summary

The TRANSCOV cohort is a multicentre observational retrospective study aiming at assessing the health impact of extra regional transfers of critically ill COVID-19 patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3,060

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 16, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 18, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

June 22, 2021

Status Verified

June 1, 2021

Enrollment Period

10 months

First QC Date

June 16, 2021

Last Update Submit

June 17, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Survival

    Status alive or dead

    1 year

Study Arms (2)

Transferred group

The transferred group includes all severe COVID patients admitted in a French ICU ward and then transferred between the 03/13/2020 and 04/10/2020 to another ICU located outside the region of the initial ICU stay.

Other: Inter ICU long distance patient transfer

Control group

The control group includes patients selected out of those whose entire ICU care has taken place in one of the hospitals which transferred patients. Up to 4 control patients will be selected for each transferred patient.

Interventions

Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.

Transferred group

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Severely ill COVID-19 patients

You may qualify if:

  • COVID-19 patients diagnosed biologically or by imaging
  • Admission in ICU between 03/13/2020 and 04/10/2020

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

EHESP

Rennes, 35043, France

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Olivier Grimaud, Ph.D., M.D.

    Ecole des Hautes Etudes en Santé Publique

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Olivier Grimaud, Ph.D., M.D

CONTACT

Christophe Fermanian, Ph.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the deparment Quantitative Methods in Public Health

Study Record Dates

First Submitted

June 16, 2021

First Posted

June 18, 2021

Study Start

March 1, 2021

Primary Completion

December 31, 2021

Study Completion

December 31, 2022

Last Updated

June 22, 2021

Record last verified: 2021-06

Locations